The Rise of China's "New Trifecta" — How AI, Robots, and Biopharma Are Reshaping Global Tech
In H1 2026, robotics, AI, and innovative biopharma — China's "New Trifecta" — drove record export growth. This article examines the data and the fundamental shift from cost-driven to innovation-driven competitiveness.
In the first half of 2026, China's total goods trade reached 25.47 trillion yuan, up 16.9% year-on-year. Behind this impressive figure, a new buzzword has captured market attention — the "New Trifecta".
Following the "Old Trifecta" (clothing, furniture, home appliances) and the "New Trifecta" (EVs, lithium batteries, solar panels), robotics, artificial intelligence, and innovative biopharma are emerging as China's next-generation export calling cards. These three future-facing industries are transitioning from isolated breakthroughs to systematic, large-scale growth.
Robotics: From Hotel Deliveries to Factory Fulfillment
Chinese robots are rapidly gaining ground worldwide. According to customs data, in the first five months of 2026, China exported 10.377 million robots across all categories, valued at 19.99 billion yuan, reaching over 150 countries and regions. Industrial robot exports grew 18.6% year-on-year, while surgical robot exports surged 3.3 times.
Yunji Technology's robots executed 750 million delivery tasks in global hotels in 2025, generating 19.06 million yuan in overseas revenue — a 92.1% year-on-year increase. More notably, Zhongke Huiling secured an order for 2,000 custom humanoid robots for shoe manufacturing, signaling that Chinese robots have moved beyond technology demonstrations into real industrial deployment.
At CES 2026, Chinese companies occupied over half of the humanoid robot exhibition booths. Unitree's quadruped and bipedal humanoid robots have become standard tools in global research and education. Zhu Keli, founding director of the Guoyan New Economy Research Institute, notes that China's robotics advantage lies in a unique "closed-loop growth mechanism" — robots are born from real-world demands, continuously refined through the country's vast manufacturing ecosystem, a dynamic few other nations can replicate.
Artificial Intelligence: From Catching Up to Leading
China's AI sector is demonstrating remarkable acceleration. OpenRouter data shows that in the third week of June 2026, Chinese LLM API call volume reached 18.81 trillion tokens per week, holding the global top spot for eight consecutive weeks.
Even more significant is the progress in foundational capabilities. In March 2026, the domestically developed Milkyway agent system topped the FutureX international benchmark, surpassing systems including Grok4. Xu Xueyin, vice president of the Zhongguancun AI Research Institute, notes that China has transitioned from catching up to leading in certain AI domains, moving from "isolated technological breakthroughs" toward "systematic capability building."
In computing infrastructure, companies like TACO are exporting power-compute coordination solutions to the Middle East, helping build large-scale AI data centers. China's expertise in AI chips and supercomputing is being replicated globally.
Biopharma: A Hundred-Billion-Dollar Wave
Innovative biopharma is perhaps the most surprising member of the New Trifecta. In the first half of 2026, China's innovative drug license-out deals totaled approximately $110 billion — already about 80% of the full-year 2025 figure and a new record.
RemeGen, leveraging first-in-class drugs, has successfully brought four innovative therapies to markets including the United States, pioneering multiple licensing models. From being known primarily for generics to becoming an innovator drug exporter, China's biopharma industry has undergone a profound transformation.
From Cost Advantage to Tech Leadership
Tracing the arc of China's trade evolution: the Old Trifecta broke into global markets through labor cost advantages; the New Trifecta seized green transition opportunities through supply chain completeness and engineering talent; now, the New Trifecta is entirely driven by foundational innovation and end-to-end self-reliance.
This is not merely product upgrading — it's a fundamental shift in industrial logic. When Yunji robots autonomously navigate Thai hospitals, when Chinese LLMs dominate global API usage charts week after week, when RemeGen's original drugs enter the US market — China is proving, one case at a time, that in the new arena of global tech competition, it has moved from chasing to leading.